secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2026-07-14T11:00:58+00:00
Accession:  0001104659-26-083326
Event type: m_and_a
Sentiment:  negative
Materiality: 1.00
Item codes: 1.01, 2.05, 5.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure to reverse merge with Avere; Avere holders get ~98% of combined co; $320M PIPE
--------------------------------------------------------------------------------

- NextCure (NXTC) to acquire Avere Therapeutics via reverse merger; Avere stockholders will own ~98.11% of combined company; NextCure stockholders ~1.89%.
- Concurrent $320M private placement from institutional investors into Avere; condition of at least $150M proceeds at close.
- NextCure to reduce workforce by substantial majority; expects ~$1.9M one-time charges in Q3 2026.
- NextCure halts new patient enrollment in SIM0505 ADC study in US; opts out of cost-sharing for LNCB74 ADC; not due to safety/efficacy.
- Pre-merger NextCure stockholders to receive CVRs entitling them to 90% of proceeds from future monetization of legacy assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926083326/0001104659-26-083326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926083326/tm2620428d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-083326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer